Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Exon 20 insertion (ex20ins) mutations are the third most common driver mutations in non-small cell lung cancer (NSCLC).
• Existing epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show limited efficacy against EGFR ex20ins mutations due to poor mutant activity and selectivity.
• Achieving high selectivity for mutant over wild-type EGFR remains a critical challenge in developing effective therapies.

Purpose of the Study:

• To evaluate the efficacy and selectivity of STX-721 as a novel inhibitor for EGFR ex20ins mutations in NSCLC.
• To address the unmet need for targeted therapies in patients with EGFR ex20ins-driven NSCLC.

Main Methods:

• In vitro and in vivo studies were conducted to assess the inhibitory activity of STX-721 against various EGFR/HER2 ex20ins mutants.
• Mutant versus wild-type EGFR selectivity was evaluated.

Main Results:

• STX-721 demonstrated potent, irreversible inhibition against a majority of EGFR/HER2 ex20ins mutants.
• Excellent selectivity of STX-721 for mutant EGFR over wild-type EGFR was observed in both in vitro and in vivo models.
• STX-721 is currently undergoing phase 1/2 clinical trials for NSCLC patients with EGFR/HER2 ex20ins mutations.

Conclusions:

• STX-721 represents a promising therapeutic candidate for NSCLC patients harboring EGFR ex20ins mutations.
• The drug's high mutant selectivity offers a potential advantage over existing TKIs, aiming to improve treatment outcomes and reduce toxicities.